Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.62 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.62 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.43 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8544217 | 1.00 | MEN1 (0.62) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| SCHEMBL2707245 | 1.00 | MEN1 (0.62) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| SCHEMBL938781 | 0.98 | MEN1 (0.65) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| SCHEMBL938780 | 0.98 | MEN1 (0.65) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| SCHEMBL940085 | 0.98 | MEN1 (0.65) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| Hydrochloric Acid SCHEMBL20449216 | 0.96 | MEN1 (0.62) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| Hydrochloric Acid SCHEMBL9080005 | 0.96 | MEN1 (0.62) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| Hydrochloric Acid SCHEMBL1764935 | 0.96 | MEN1 (0.62) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| Hydrochloric Acid SCHEMBL28855198 | 0.94 | CYP2D6 (0.61) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| Hydrochloric Acid SCHEMBL28855199 | 0.94 | CYP2D6 (0.61) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020169156-A1 | Azacyclooctane and heptane derivatives, their preparation and use in therapy | NEUROSEARCH A/S | 2002-11-14 | — | — | US | claimed |
| EP-0705259-B1 | PHENYRROLE DERIVATIVES AND THEIR USE AS DOPAMINE D3 ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1998-02-25 | — | — | EP | disclosed |
| US-5637600-A | PSYCHOLOGICAL DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 1997-06-10 | — | — | US | disclosed |
| EP-0745079-A1 | PHENYLPYRROLE DERIVATIVES AND THEIR USE AS DOPAMINE D3 ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1996-12-04 | — | — | EP | disclosed |
| EP-0734378-A1 | AMINOSULPHONYL-PHENYL-1H-PYRROLE DERIVATIVES, METHOD OF THEIR PREPARATION AND THEIR USE | SMITHKLINE BEECHAM PLC (GB) | 1996-10-02 | — | — | EP | disclosed |
| EP-0705259-A1 | PHENYRROLE DERIVATIVES AND THEIR USE AS DOPAMINE D3 ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1996-04-10 | — | — | EP | disclosed |
| WO-1995022542-A1 | PHENYLPYRROLE DERIVATIVES AND THEIR USE AS DOPAMINE D3 ANTAGONISTS | SMITHKLINE BEECHAM P.L.C. (GB) | 1995-08-24 | — | — | WO | disclosed |
| WO-1995016674-A1 | AMINOSULPHONYL-PHENYL-1H-PYRROLE DERIVATIVES, METHOD OF THEIR PREPARATION AND THEIR USE | SMITHKLINE BEECHAM PLC (GB) | 1995-06-22 | — | — | WO | disclosed |
| WO-1995010504-A1 | 2-(1-ALKOXY-2-NAPHTHALENYL)-PYRROLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS DOPAMINE D3 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1995-04-20 | — | — | WO | disclosed |
| WO-1995000508-A1 | PHENYRROLE DERIVATIVES AND THEIR USE AS DOPAMINE D3 ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1995-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169156-A1 | Azacyclooctane and heptane derivatives, their preparation and use in therapy | CHRNA1, CHRNB1, CHRNA3 | MEN1 3141/4885CYP2D6 1142/4885CYP2C19 1698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.